Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 3370
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT06847724 Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocr… |
CYB704 | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Sandoz | United States, Bosnia and Herzegovina, Bulgaria, Croa… | 2025-06-10 → 2027-05 | Ouvrir |
| NCT06220669 A Study of LY3541860 in Adult Participants With Relapsing Multiple Scle… |
LY3541860 | SEP | Phase 2 | TERMINATED | En attente / non publié | Eli Lilly and Company | United States, France, Italy, Latvia, Poland, Slovaki… | 2024-03-19 → 2026-07-13 | Ouvrir |
| NCT03958877 A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (… |
BIIB017 (peginterferon beta-1a) | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Biogen | United States, Argentina, Australia, Belgium, Bulgari… | 2019-10-18 → 2027-05-20 | Ouvrir |
| NCT07842302 NIBS_MSf — Fighting Fatigue in Multiple Sclerosis: TMS vs. tDCS Efficac… |
TMS | SEP | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Universitat Oberta de Catalunya | Non communiqué | 2026-09 → 2029-09 | Ouvrir |
| NCT03822858 Expanded Access to Intrathecal Administration of Autologous Mesenchymal… |
Intrathecal MSC-NP injection | SEP | À vérifier | NO_LONGER_AVAILABLE | En attente / non publié | Tisch Multiple Sclerosis Research… | United States · Tisch MS Research Center of New York,… | Non communiqué | Ouvrir |
| NCT07840924 The CanISleepinMS Study: Effect of Cannabidiol (CBD) on Sleep Quality i… |
Cannabidiol Oil | SEP | Phase 2 | COMPLETED | En attente / non publié | Wageningen University | Netherlands · Rijnstate, Arnhem, Netherlands | 2024-03-26 → 2026-03-28 | Ouvrir |
| NCT07840326 A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary P… |
SUN-627 | SEP | Phase 2 | RECRUITING | En attente / non publié | Sundance Biosciences, Inc. | United States · Local Institution - Site 101, Raleigh… | 2026-10 → 2027-07 | Ouvrir |
| NCT05835622 EXHOMESEP — Clinical Investigation of the Quality of Life Benefit of Us… |
Keeogo | SEP | Non applicable | COMPLETED | En attente / non publié | Pôle Saint Hélier | France · Centre de rééducation Fonctionnelle Propara-… | 2024-02-01 → 2026-09-18 | Ouvrir |
| NCT07299019 A Study of Orelabrutinib in Patients With Secondary Progressive Multipl… |
Orelabrutinib | SEP | Phase 3 | RECRUITING | En attente / non publié | Zenas BioPharma (USA), LLC | United States, Bulgaria, Croatia, Czechia, Estonia, G… | 2026-03-23 → 2030-07 | Ouvrir |
| NCT05119569 FENopta — A Study to Investigate the Efficacy of Fenebrutinib in Relaps… |
Fenebrutinib | SEP | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Bosnia and Herzegovina, Croatia, Czech… | 2022-03-01 → 2027-06-30 | Ouvrir |
| NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety … |
Ocrelizumab | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia… | 2018-07-12 → 2025-07-17 | Ouvrir |
| NCT06590545 IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis |
KYV-101, an autologous fully-huma… | SEP | Phase 1/2 | NOT_YET_RECRUITING | En attente / non publié | David Simon | Non communiqué | 2025-01 → 2027-07 | Ouvrir |
| NCT06500273 ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Pa… |
cemacabtagene ansegedleucel | SEP | Phase 2 | RECRUITING | En attente / non publié | Allogene Therapeutics | United States, Australia, Canada, South Korea · Adven… | 2024-06-18 → 2032-12 | Ouvrir |
| NCT07443137 CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 … |
rapcabtagene autoleucel (YTB323) | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Stanford University | Non communiqué | 2026-09 → 2028-08 | Ouvrir |
| NCT05691153 ThisCART19A for B-NHL Relapsed After Auto-CAR T |
ThisCART19A with Dose Level 1 | SEP | Phase 1 | UNKNOWN | En attente / non publié | The First Affiliated Hospital of … | China · The First Affiliated Hospital of Soochow Univ… | 2022-12-01 → 2025-11-30 | Ouvrir |
| NCT07360288 TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory F… |
TC011 single-arm | SEP | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | TICAROS Co., Ltd. | Non communiqué | 2026-03-01 → 2030-02-28 | Ouvrir |
| NCT06420154 The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relap… |
anti-CD19-CAR-T cells | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | First Affiliated Hospital of Wenz… | China · The First Affiliated Hospital of Wenzhou Medi… | 2024-05-27 → 2027-05-27 | Ouvrir |
| NCT04499573 Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults W… |
CD19/CD22 CAR-T | SEP | Phase 1/2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Federal Research Institute of Ped… | Russia · Federal Research Institute of Pediatric Hema… | 2020-07-27 → 2027-03-13 | Ouvrir |
| NCT03810196 CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infect… |
CliniMACS Cell Processing System … | SEP | Non applicable | RECRUITING | En attente / non publié | Children's Hospital of Philadelph… | United States · Children's Hospital of Philadelphia, … | 2019-03-01 → 2028-07 | Ouvrir |
| NCT07188558 PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Ch… |
rondecabtagene autoleucel | SEP | Phase 3 | RECRUITING | En attente / non publié | Lyell Immunopharma, Inc. | United States · AdventHealth, Orlando, United States … | 2026-01-12 → 2032-01 | Ouvrir |
| NCT00434629 Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Resi… |
Bexxar | SEP | Phase 1 | COMPLETED | En attente / non publié | University of Pennsylvania | United States · Abramson Cancer Center, University of… | 2007-02 → 2015-05 | Ouvrir |
| NCT06248086 A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive… |
ASP2802 | SEP | Phase 1 | TERMINATED | En attente / non publié | Astellas Pharma Global Developmen… | Australia · Site AU61004, Sydney, Australia | 2024-09-06 → 2024-12-01 | Ouvrir |
| NCT00006669 Rituximab Followed by Combination Chemotherapy in Treating Patients Wit… |
Rituximab | SEP | Phase 2 | WITHDRAWN | En attente / non publié | National Cancer Institute (NCI) | United States · Franklin Square Hospital Center, Balt… | 1999-09 → 2000-01 | Ouvrir |
| NCT02772822 A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide,… |
SCT400 plus CHOP | SEP | Phase 3 | UNKNOWN | En attente / non publié | Sinocelltech Ltd. | China · Cancer Hospital Chinese Academy of Medical Sc… | 2016-06 → 2019-12 | Ouvrir |
| NCT03636503 Rituximab + Immunotherapy in Follicular Lymphoma |
Rituximab | SEP | Phase 1 | TERMINATED | En attente / non publié | National Cancer Institute (NCI) | United States · City of Hope, Duarte, United States |… | 2018-10-30 → 2023-07-30 | Ouvrir |